“Renal denervation has travelled a very storied path over the last 10–15 years,” David Kandzari (Atlanta, USA) tells Cardiovascular News, commenting that initial unbridled enthusiasm turned to disillusionment over the prospects of renal denervation as a device-based treatment for hypertension.
However, the field has been “revitalised”, he says, noting that there have been five successive sham-controlled trials showing statistically significant and clinically meaningful in blood pressure. Kandzari offers an overview of SPYRAL HTN-ON MED data presented at EuroPCR 2022 (17–20 May, Paris, France) demonstrating improved blood pressure control with significantly higher time in target range after radiofrequency renal denervation when compared to sham through three years, as well as other studies presented at the event, and considers the future value of renal denervation as a device-based treatment for hypertension.
